Health & Research

Hepatitis C-A Silent Storm: A Review on Recent Data

Abstract

Hepatitis C virus (HCV) is recognized as a major health care problem and increasing frequently in the world and also raising high in Pakistan.

Worldwide 180 million people have been infected with hepatitis C virus and 700,000 die each year from HCV- related liver disease or hepatocellular carcinoma. Pakistan carries one of the highest burdens of chronic hepatitis and mortality due to liver failure and hepatocellular carcinoma. In Pakistan 17 million people are suffering from hepatitis C. Blood transfusion is still the major cause of transmission in the country. This comprehensive review of hepatitis C genotype, prevalence, transmission and treatment focuses on current trends policies and directions.

Keywords:

Hepatitis C virus, Anti-HCV, HCV, Distribution Patterns, Geographical regions, Pakistan

Introduction:

Hepatitis C is a liver disease caused by the hepatitis C virus. The virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to serious, lifelong illness (WHO July 2016). According to WHO Approximately 700,000 people die each year from hepatitis C-related disease. Hepatitis C is a viral disease of the liver that in the long run leads liver to turn out to be swollen and inflammation happens (Lam et al., 2010). Hepatitis virus is an infectious agent that causes cirrhosis and carcinoma of liver mobile component all over the world (Kazemi et al., 2008).

Hepatitis C virus belongs to family flaviviridae, which additionally include classical flaviviruses like as one of yellow fever and dengue (Pfaender et al., 2015). HCV is small in length of about 55 to 65 nm. The structure of HCV contains a single stranded RNA, which is enveloped and has a positive charge on it. Hepatitis C is a problem throughout the world; about 170 million people are victim of HCV. In general population of Pakistan, the prevalence of HCV 4.9% most prevalent genotype is 3(GT_3) 3 which is 79%and after that there is a prevalence of genotype I (GT_1); 2,4,5,6 and 7 are less prevalent genotypes (Kuo et al., 2016). Hepatitis C virus (HCV) is a globally regular pathogen and a main cause of death and morbidity (Regulate et al., 2011).

The maximum current estimates of ailment burden display an growth in seroprevalence over the last 15 years to 2.8%, equating to >185 million infections worldwide. The occurrence of HCV contamination is lowering, recently global deaths from liver ailment secondary to HCV contamination will preserve to boom over the following twenty years 12 out of 25 percent of sufferers uncovered to hepatitis C surmounts the infection obviously, however the final 75% face persistent or lifestyles-lengthy HCV contamination (Waheed et al., 2009).

HCV has frequently been known as the “silent virus,” as maximum HCV infections are clinically silent till the illness reaches a past due degree, which frequently takes place several years after initial contamination. Continual HCV infection is many of the maximum not unusual causes of cirrhosis and hepatocellular carcinoma, and the most common indication for liver transplantation (Hazarezadeh et al., 2013). Re-occurrence of HCV infection after liver transplantation is prevalent and a leading cause of graft failure (Joshe et al., 2014).

Efforts to broaden direct-acting antivirals (DAAs) for HCV treatment have long been hampered by means of the absence of an efficient cellular tradition device for propagation of HCV. Extensive studies efforts over the last too many years have resulted in the development of HCV sub genomic replicons, capable of self-sufficient replication (Lohmann et al., 1999),  and strong infectious mobile lifestyle models for HCV infection (Wakita et al., 2005; zhong et al., 2016), that no longer simplest provide the opportunity to dissect mechanisms of the viral existence cycle, but also facilitate the development of large-scale, high-through put screening assays to pick out antiviral goals and to broaden surprisingly powerful anti-HCV compounds (Lindenbach et al., 2013).

Genome of Hepatitis C:

HCV RNA genome has a single open studying frame made from 9600 nucleotide bases lengthy. Furthermore, 2 enveloped protein E1 and E 2 core protein incorporates structural and non-structural proteins in compasses NS1, NS2, NS3, NS4a, NS4b, NS5a, NS5b (Smith et al., 2014). Phylogenetic and series evaluation of complete viral genome splits HCV into 7 principle genotype. HCV in addition is further categorized into 67 confirmed and 20 provisional sub-types (Mohd et al., 2013). (HCV) is a member of the Flaviviridae circle of relatives, which additionally includes classical flaviviruses such as the ones of yellow fever and dengue.

HCV is an enveloped virus with variety, obviously infecting only humans and chimpanzees, even though the origin of HCV still remains elusive. HCV is classed in the genus Hepacivirus of the Flaviviridae family, and the closest genetic relative to HCV is a non-primate hepacivirus, which infects horses (Pfaender et al., 2015). Phylogenetic and series evaluation of complete viral genomes splits HCV into seven principle genotypes. HCV genotypes had been in addition categorized into sixty seven confirmed and 20 provisional sub-types (Smith et al., 2014).

In the world HCV genotype 1(GT_1) is the most conventional genotype (46% of all HCV cases), followed by genotype 3 (30%). Genotypes 2, 4  and 6 are chargeable for 23% of all HCV cases and genotype 5 is least common for less than 1% of all HCV cases (Messina et al., 2015). Genotype 7 has been remote handiest in a affected person from crucial Africa In a recently conducted meta-analysis, the number of human beings with anti-HCV antibodies has been estimated at 185 million in 2005, or 2.8% of the human populace, with an estimation of a hundred thirty to hundred seventy million humans are chronically infected (Mohd et al., 2013).

Prevalence of Hepatitis C:

Hepatitis C virus is the main cause of chronic liver disease, according to an estimation, in the world there are 170-200 million people are infected and in Pakistan about 17 million people are suffering from it(Khan et al.,2014). Hepatitis C is amongst critical public health difficulty worldwide, with over 170-200 million people are suffering and in Pakistan 17 million people are infected (Saleha et al.,2014).Hepatitis C occurs due to Hepatitis C virus is a transmissible disease of the liver which causes viral infection in more than 170 million people in the world and about 16 million in Pakistan (Khan et al.,2013). According to an estimation of World Health Organization that 180 million people are affected with Hepatitis C in 2009.3-4 million people are affected per year.2/3 newly affected people adopt chronic liver disease (Umar et al., 2012). WHO relates hepatitis to“ Viral Time Bomb” and reports 180 million people are suffering from hepatitis C virus out of which 130 million people are chronically ill and at a risk of liver disease or liver damage (Umar et al., 2010).

In the world anti_HCV prevalence from population dependent studies are used due HCV infection (Hanafih et al.,2013). Historically, the prevalence in African and Asian countries is reported highest as compared to developed countries like North America, Western Europe and Australia (WR et al.,2010).HCV is going to be a major health problem of underdeveloped nations also in Pakistan that has 2nd highest prevalence of about 4.5% to 8%(Jiswani et al., 2011). Pakistani studies based on small targeted groups that consist of blood donors, healthcare persons, drug abusers and chronically liver damaged patients showed as high prevalence of 40% (MJ et al., 2010). Every year 35,000 deaths occurred due to hepatitis C virus (Hanafih et al., 2013).

Transmission Routes:

HCV transmission happens through blood-to-blood contact. In the early Nineties, advent of present day anti-HCV screening assessments, such as the detection of HCV-precise antibodies and HCV RNA (Kuo et al., 2016), almost completely eliminated transmission of HCV through blood transfusions and organ transplants. Injection drug use is currently the primary transmission path for HCV infection, which generally occurs while blood-contaminated needles and syringes are shared dangerous clinical approaches, inclusive of the reuse of single-use medical devices, stay a main mode of HCV transmission in growing countries (Alter et al., 2011).

Re-occurrence of HCV infection after liver transplantation is prevalent and a leading cause of graft failure (Joshe et al., 2014). Efforts to broaden direct-acting antivirals (DAAs) for HCV treatment have long been hampered by means of the absence of an efficient cellular tradition device for propagation of HCV. Extensive studies efforts over the last two many years have resulted in the development of HCV sub genomic replicons, capable of self sufficient replication (Lohmann et al., 1999), and strong infectious mobile lifestyle models for HCV infection (Wakita et al., 2005; Zhong et al., 2016). That no longer simplest provide the opportunity to dissect mechanisms of the viral existence cycle, but also facilitate the development of large-scale, high-through put screening assays to pick out antiviral goals and to broaden surprisingly powerful anti-HCV compounds (Lindenbach et al., 2005).

Complications Regarding Hepatitis C:

Chronic HCV infection is related to the development of liver cirrhosis, hepatocellular cancer, liver failure, and death, and HCV is now the maximum not unusual reason of death in HIV-effective sufferers on quite energetic antiretroviral remedy (Cookie et al., 2013). Chronic HCV infection can cause extreme liver disorder, consisting of cirrhosis, hepatic decomposition and hepatocellular carcinoma (HCC), with an interval of 20-30 years after being uncovered to HCV. (Laur et al., 2001). The world health employer’s global Burden of disease 2000 project predicted in 2002 that the attributable cirrhosis and liver cancer deaths due to HCV infection globally were 211000 and 155000 respectively. (Razavi et al., 2013).

Similarly, chronic HCV contamination is associated with numerous extra hepatic manifestations, which include mixed cryoglobulinemia vasculitis, type 2 diabetes, lympho pro life operative disorders, renal ailment and rheumatic disorders (Joshi et al., 2014). Large research attempt has been devoted to understanding the heterogeneous scientific final results of HCV contamination. For the duration of the chronic section of HCV infection, HCV-specific T cells are down-regulated and display an exhausted and dysfunctional phenotype. Persistent liver infection, prompted with the aid of HCV, promotes the technology of T regulatory cells, which contributes to similarly suppression of the HCV specific T cellular response (Reherman et al., 2013).

Recommended Treatments:

A revolution is occurring in the therapy for hepatitis C. Many types of new drugs for the treatment of hepatitis C virus (HCV) are now available in the market and other such as direct-acting antivirals and host-targeted agents, are in phase I or phase III clinical development. more than 90% of infections are expected to cured by oral, interferon-free combinations of drugs. (Pawlotsky 2014).

[A] Summary of Recommended Preferred Regimens with Treatment Duration (WHO Guidelines for Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. April 2016)

  1. Persons without Cirrhosis:
Daclatasvir/SofosbuvirLedipasvir/SofosbuvirSofosbuvir/Ribavirin
Genotype 112 Weeks12 Weeks
Genotype 212 Weeks
Genotype 312 Weeks24 Weeks
Genotype 412 Weeks12 Weeks
Genotype 512 Weeks
Genotype 612 Weeks

 

Reference: Treatment duration are adapted from 2015 guidelines of American Association for the study of liver disease (AASLD) and European Association for the study of Liver (EASL).

  1. Persons with Cirrhosis:
Daclatasvir/

Sofosbuvir/

Daclatasvir/

Sofosbuvir/

Ribavirin

Ledipasvir/

Sofosbuvir

Ledipasvir/

Sofosbuvir/

Ribavirin

Sofosbuvir/

Ribavirin

Genotype 124 weeks12 weeks24 weeks12 weeks
Genotype 216 weeks
Genotype 324 weeks
Genotype 424 weeks12 weeks24 weeks12 weeks
Genotype 524 weeks12 weeks
Genotype 624 weeks12 weeks

 

Reference: Treatment duration are adapted from 2015 guidelines of American Association for the study of liver disease (AASLD) and European Association for the study of Liver (EASL).

[B] Summary of Recommended Alternative Regimens with Treatment Duration: (Guidelines for Screening, Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. April 2016)

  1. Persons without Cirrhosis:
Simiprevir/

Sofosbuvir/

Daclatasvir/

Sofosbuvir/

Ombtiasvir/

Paritaprevir/

Ritonavir/

Dasabuvir

Ombitasvir/

Paritaprevir/

Ritonavir/

Ribavirin

 

Sofosbuvir/

Pegylated interferon/

Ribavirin

Genotype 112 weeks12 weeks
Genotype 212 weeks
Genotype 3
Genotype 412 weeks12 weeks
Genotype 512 weeks
Genotype 612 weeks

Reference: Treatment duration are adapted from 2015 guidelines of American Association for the study of liver disease (AASLD) and European Association for the study of Liver (EASL).

  1. Persons with Cirrhosis:
Daclatasvir/

Sofosbuvir/

Simiprevir/

Sofosbuvir

Simiprevir/

Sofosbuvir/

Ribavirin

Ombtiasvir/

Paritaprevir/

Ritonavir/

Dasabuvir

Ombtiasvir/

Paritaprevir/

Ritonavir/

Ribavirin

Sofosbuvir/

Pegylated interferon/

Ribavirin

Genotype 124 weeks12 weeks24 weeks
Genotype 212 weeks
Genotype 312 weeks
Genotype 424 weeks12 weeks24 weeks
Genotype 512 weeks
Genotype 612 weeks

Reference: Treatment duration are adapted from 2015 guidelines of American Association for the study of liver disease (AASLD) and European Association for the study of Liver (EASL).

Conclusion:

The frequency of hepatitis C virus in Pakistan is very high (8%), varying from 0.4%-33.7%, indicating pockets of infections.The frequency is significantly higher than in surrounding countries.The contribution of this high frequency to premature mortality and disability calls for massive awareness campaigns.

Reference:

  1. World Health Organization. Hepatitis C. Available at: www.who.int/vaccine_research/viral_cancers. Retrieved on 16-04-2016.
  2. Waqar M, Khan AU, Rehman HU, Idrees M, Wasim M, Ali A, et al. Determination of hepatitis C virus genotypes circulating in different districts of Punjab (Pakistan).Eur J Gastroenterol Hepatol. 2014;26(1):59–64. doi: 10.1097/MEG.0b013e328362dc3f. [PubMed] [Cross Ref]
  3. Rouabhia S, Sadelaoud M, Chaabna-Mokrane K, Toumi W, Abenavoli L. Hepatitis C virus genotypes in north eastern Algeria: A retrospective study.World J Hepatol. 2013;5(7):393–7. doi: 10.4254/wjh.v5.i7.393. [PMC free article] [PubMed] [Cross Ref
  4. Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients.Hepat Mon. 2013;13(1) doi: 10.5812/hepatmon.7991.[PMC free article] [PubMed] [Cross Ref]
  5. Attaullah S, Khan S, Ali I. Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J. 2011;8:433. doi: 10.1186/1743-422X-8-433. [PMC free article] [PubMed] [Cross Ref]
  6. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China.J Gastroenterol Hepatol. 2013;28 Suppl 1:7–10. doi: 10.1111/jgh.12220. [PubMed] [Cross Ref]
  7. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin
  8. Microbiol Infect 2011; 17: 107-115 [PMID: 21091831 DOI:10.1111/j.1469-0691.2010.03432.x]
  9. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and naturalhistory of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10:
  10. 553-562 [PMID: 23817321 DOI: 10.1038/nrgastro.2013
  11. .Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors.
  12. World J Gastroenterol 2009;
  13. Khan N, Akmal M, Hayat M, Umar M, Ullah A, Ahmed I, Rahim K, Ali S, Bahadar S, Saleha S. Geographic distribution of hepatitis
  14. C virus genotypes in pakistan. Hepat Mon 2014; 14: e20299 [PMID: 25477975 DOI: 10.5812/hepatmon.20299
  15. Umer M et al . HCV prevalence and genotypes in Pakistan
  16. Med Assoc 2010;
  17. 14 Saleha S, Kamal A, Ullah F, Khan N, Mahmood A, Khan S.Prevalence of hepatitis C virus genotypes in district bannu, khyber
  18. pakhtunkhwa, pakistan. Hepat Res Treat 2014; 2014: 165826 PMID: 25093120 DOI: 10.1155/2014/165826
  19. Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after
  20. liver transplantation-mechanisms, assessment and therapy. Nat Rev
  21. Gastroenterol Hepatol 2014; 11: 710-721 [PMID: 25023032 DOI:

10.1038/nrgastro.2014.114]

 

  1. Pfaender S, Cavalleri JM, Walter S, Doerrbecker J, Campana

B, Brown RJ, Burbelo PD, Postel A, Hahn K, Anggakusuma N,

Baumgärtner W, Becher P, Heim MH, Pietschmann T, Feige K,

Steinmann E. Clinical course of infection and viral tissue tropism

of hepatitis C virus-like nonprimate hepaciviruses in horses.

Hepatology 2015; 61: 447-459 [PMID: 25212983 DOI: 10.1002/

hep.27440]

2 Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton

JT, Simmonds P. Expanded classification of hepatitis C virus

into 7 genotypes and 67 subtypes: updated criteria and genotype

assignment web resource. Hepatology 2014; 59: 318-327 [PMID:

24115039 DOI: 10.1002/hep.26744]

3 Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS,

Pybus OG, Barnes E. Global distribution and prevalence of

hepatitis C virus genotypes. Hepatology 2015; 61: 77-87 [PMID:

25069599 DOI: 10.1002/hep.27259]

4 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global

epidemiology of hepatitis C virus infection: new estimates of agespecific

antibody to HCV seroprevalence. Hepatology 2013; 57:

1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]

5 Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH,

Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for

HCV basic research

HCV treatment

1986 1989 1998 1999 2001 2005 2009 2011 2013 2014 2015/2016 20…

Identification of HCV HCV subgenomic replicon

HCV cell culture system

IL28B polymorphism

HCV life cycle in humanized mice

17 Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus

entry and assembly. Nat Rev Microbiol 2013; 11: 688-700 [PMID:

24018384 DOI: 10.1038/nrmicro3098]

Tags

anumnu

Hello, my nick name is Anumnu! Fact Scholar is a daily updated blog about Fashion & Beauty, Ethics, Health Fitness, Research Article, Stories and everyday moments from all over the world.

Related Articles

Close
Close